Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | JAK1 A723D |
| Therapy | Ruxolitinib |
| Indication/Tumor Type | cancer |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| JAK1 A723D | cancer | sensitive | Ruxolitinib | Preclinical | Actionable | In a preclinical study, transformed cells harboring JAK1 A723D were sensitive to ATP-competitive JAK inhibitors, such as Jakafi (Ruxolitinib) (PMID: 21393331). | 21393331 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (21393331) | Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors. | Full reference... |